A revival of bispecific antibodies

被引:127
作者
Kufer, P
Lutterbüse, R
Baeuerle, PA
机构
[1] Micromet AG, D-81477 Munich, Germany
[2] Inst Immunol, D-80336 Munich, Germany
关键词
D O I
10.1016/j.tibtech.2004.03.006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of bispecific antibodies have been developed but only a few have advanced to clinical trials. Here, we give a brief history of bispecific antibodies and review very recent progress towards formats that are beginning to solve the major issues of earlier formats. These improved bispecific antibodies are expected to show clinical efficacy in patients with cancer and other diseases, in a way that monoclonal antibodies have shown in recent years.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 86 条
[1]  
Baeuerle PA, 2003, CURR OPIN MOL THER, V5, P413
[2]  
Blok VT, 1998, J IMMUNOL, V160, P3437
[3]  
BOLHUIS RLH, 1992, INT J CANCER, P78
[4]   PREPARATION OF BISPECIFIC ANTIBODIES BY CHEMICAL RECOMBINATION OF MONOCLONAL IMMUNOGLOBULIN-G1 FRAGMENTS [J].
BRENNAN, M ;
DAVISON, PF ;
PAULUS, H .
SCIENCE, 1985, 229 (4708) :81-83
[5]   REGRESSION OF ADVANCED OVARIAN-CARCINOMA BY INTRAPERITONEAL TREATMENT WITH AUTOLOGOUS T-LYMPHOCYTES RETARGETED BY A BISPECIFIC MONOCLONAL-ANTIBODY [J].
CANEVARI, S ;
STOTER, G ;
ARIENTI, F ;
BOLIS, G ;
COLNAGHI, MI ;
DIRE, EM ;
EGGERMONT, AMM ;
GOEY, SH ;
GRATAMA, JW ;
LAMERS, CHJ ;
NOOY, MA ;
PARMIANI, G ;
RASPAGLIESI, F ;
RAVAGNANI, F ;
SCARFONE, G ;
TRIMBOS, JB ;
WARNAAR, SO ;
BOLHUIS, RLH .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (19) :1463-1469
[6]   Approaches to implement bispecific antibody treatment of ovarian carcinoma [J].
Canevari, S ;
Mezzanzanica, D ;
Mazzoni, A ;
Negri, DRM ;
Figini, M ;
Ramakrishna, V ;
Bolis, G ;
Colnaghi, MI .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (3-4) :187-189
[7]   The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs inVL-to-VH orientation:: Implications for diabody flexibility [J].
Carmichael, JA ;
Power, BE ;
Garrett, TPJ ;
Yazaki, PJ ;
Shively, JE ;
Raubischek, AA ;
Wu, AM ;
Hudson, PJ .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 326 (02) :341-351
[8]  
Cochlovius B, 2000, CANCER RES, V60, P4336
[9]   Clinical experience with CD64-directed immunotherapy. An overview [J].
Curnow, RT .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (3-4) :210-215
[10]  
De Gast G C, 1995, J Hematother, V4, P433, DOI 10.1089/scd.1.1995.4.433